FIELD: pharmaceuticals.
SUBSTANCE: invention describes the compound of formula (I).
The invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt thereof
where R1 is selected from -(C1-6 alkyl), R2 is selected from -(C1-6 alkyl), R3 is selected from 2-amino-2-adamantanecarboxylic acid, and Z is -(linker group)-( chelator group), where the linker group is -C1-6 alkylene-N(R4)-C1-6 alkylene-N(R4)-, where each R4 is independently selected from hydrogen and C1-6 alkyl, and each C1-6 alkylene is independently optionally substituted with one substituent selected from OH, where the chelator group is selected from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 6-hydrazinonicotinic acid (HYNIC) and 2-amino-3-(1-(2-carboxyethyl)-1H-1,2,3-triazol-4-yl)propanoic acid, as well as a compound complex with one or more diagnostically or therapeutically effective radionuclides selected from Cu-62, Cu-64, Cu-67, Tc-99m, Lu-177 and Ac-225, as well as pharmaceutical compositions based on it for the diagnosis and/or treatment of a disorder involving the neurotensin 1 receptor.
EFFECT: obtaining new compounds and complexes that can be used for the diagnosis and/or treatment of a disorder involving the neurotensin 1 receptor.
11 cl, 2 tbl, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | 2016 |
|
RU2741000C2 |
RAD51 INHIBITORS | 2018 |
|
RU2795882C2 |
CD73 INHIBITOR, ITS PRODUCTION METHOD AND ITS USE | 2020 |
|
RU2787428C1 |
IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | 2020 |
|
RU2785124C1 |
DUAL ATM AND DNA-PK INHIBITORS FOR ANTITUMOR THERAPY | 2020 |
|
RU2800756C1 |
N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION | 2018 |
|
RU2765785C2 |
CHEMOKINE RECEPTOR MODULATORS AND USE THEREOF | 2017 |
|
RU2768827C2 |
BIARYL DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2768830C2 |
COMPOUND BASED ON PYRROLAMIDOPYRIDONE, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2809596C2 |
COMPOUNDS FOR TREATING CANCER | 2011 |
|
RU2609018C2 |
Authors
Dates
2023-05-25—Published
2017-08-02—Filed